Clinical and Diagnostic Laboratory Immunology, September 1999, p. 713-717, Vol. 6, No. 5
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Retrovirus Disease Branch, Division of AIDS, STD, and TB Laboratory Research, National Centers for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia1; Second Department of Internal Medicine, Miyazaki Medical College, 5200 Kihara, Miyazaki, Japan2; and Harvard School of Public Health, Harvard University, Boston, Massachusetts3
Received 25 January 1999/Returned for modification 14 April 1999/Accepted 24 May 1999
To determine the mechanism of the purified protein derivative
(PPD)-specific hyporesponsiveness in Mycobacterium bovis
BCG-vaccinated human T-cell leukemia virus type 1 (HTLV-1)-infected
individuals, we examined cytokine production in response to PPD in the
following four groups of individuals: (i) HTLV-negative, PPD
nonresponders (n = 11; NN); (ii) HTLV-negative, PPD
responders (n = 18; NP); (iii) HTLV-positive, PPD
nonresponders (n = 15; PN); and (iv) HTLV-positive,
PPD responders (n = 15; PP). In vitro stimulation with
PPD resulted in both proliferative responses and gamma interferon (IFN-
) production in NP and PP (P < 0.02), with
minimal proliferation and IFN-
production in the NN and PN groups.
Further, PPD-specific interleukin 10 (IL-10) production was
significantly reduced in the PN group (P < 0.01),
while the other groups had comparable levels. Cytokine reconstitution
experiments demonstrated that while addition of recombinant IL-12
(rIL-12) plus anti-IL-4 restored PPD-specific responses in the NN
group, it had no effect in the PN group. However, addition of rIL-12
resulted in the increased production of IFN-
in both nonresponder
groups (NN and PN), suggesting that the lack of IFN-
production was
not responsible for the PPD anergy. We conclude that PPD-specific
anergy in HTLV-1-infected individuals appears to be due in part to
their inability to respond to rIL-12.
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |